Siegfried Holding AG ( (SGFEF) ) has released its Q4 earnings. Here is a breakdown of the information Siegfried Holding AG presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Siegfried Holding AG, a global pharmaceutical supplier, specializes in developing and manufacturing active pharmaceutical ingredients and finished pharmaceutical products, serving the pharmaceutical industry with sites across Europe, the USA, and Asia.
In its 2024 financial report, Siegfried Holding AG demonstrated continued profitable growth despite currency headwinds and the phase-out of its vaccine business. The company’s net sales rose to CHF 1,294.6 million, marking a 1.8% increase, supported by a robust business performance and strategic cost management.
Key financial metrics highlighted in the report include a 2.7% increase in core gross profit, reaching CHF 329.1 million, and an enhanced core EBITDA of CHF 285.6 million, reflecting a 4.5% growth. Notably, the core net profit surged by 24% to CHF 158.9 million, with a corresponding margin improvement to 12.3%. Siegfried also converted hybrid bonds into equity, strengthening its financial standing with an equity ratio of 50.7%.
However, the company faced a decline in operating cash flow to CHF 168.8 million, impacted by higher income tax payments and changes in net working capital. Investments in property, plant, equipment, and intangible assets increased to CHF 180.8 million, contributing to a negative free cash flow of CHF 11.6 million.
Looking ahead, Siegfried Holding AG remains focused on operational efficiency and cost management, with the management expressing confidence in the company’s strategic direction and its ability to support future growth initiatives.
